Pharmacokinetics of favipiravir in critically ill patients with COVID‐19

…, R Tamura, M Eto, H Ikesue, N Muroi… - Clinical and …, 2020 - Wiley Online Library
… The intra-assay accuracy (relative error %, n = 5) and precision (relative SD %, n = 5) were
1.9–4.9% and 90.1–96.4%, respectively. The inter-assay accuracy and precision (n = 3) were …

[HTML][HTML] Anaphylaxis from the carboxymethylcellulose component of barium sulfate suspension

N Muroi, M Nishibori, T Fujii, M Yamagata… - … England Journal of …, 1997 - Mass Medical Soc
… To examine the effect of N-formyl-methionyl-leucyl-phenylalanine, 18 it was added to the
leukocyte suspension instead of carboxymethylcellulose. The reaction was stopped by cooling …

[HTML][HTML] Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone …

…, H Tomita, M Hirabatake, M Ikemura, N Muroi… - Supportive Care in …, 2021 - Springer
… (n = 97), received zoledronic acid for the treatment of hypercalcemia (n = 54), received both
denosumab and zoledronic acid (n … up for at least 1 month following treatment (n = 8) (Fig. 1). …

[HTML][HTML] Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score …

…, K Doi, M Morimoto, M Hirabatake, N Muroi… - Supportive Care in …, 2022 - Springer
… of hypercalcemia (n = 163), lacked dental examinations before starting denosumab or ZA
treatment (n = 148), or could not be followed up for 1 month after the start of BMA treatment (n = …

[HTML][HTML] Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases

…, K Doi, M Morimoto, M Hirabatake, N Muroi… - Cancer Chemotherapy …, 2021 - Springer
… ZA for the treatment of hypercalcemia (n = 163), did not undergo … (n = 148), could not be
followed up for at least 1 month after treatment (n = 82), or switched from denosumab to ZA (n = 4…

Population pharmacokinetics of favipiravir in patients with COVID‐19

…, R Tamura, M Eto, H Ikesue, N Muroi… - CPT …, 2021 - Wiley Online Library
… standard deviation percentage; n = 5) and accuracy (relative error percentage; n = 5) were
3.1%–… Aldehyde oxidases inhibitor 4 (amlodipine [n = 8] and metoclopramide [n = 5]) and IMV-…

[HTML][HTML] Association between 25-hydroxyvitamin D levels and COVID-19 severity

…, H Ikesue, M Eto, T Hashida, K Tomii, N Muroi - Clinical Nutrition …, 2022 - Elsevier
Background and aims Despite reports on the impact of vitamin D status on coronavirus
disease 2019 (COVID-19) severity, the association between low vitamin D status and severe …

New types of anodes for the oxygen evolution reaction in acidic solution

Y Matsumoto, T Tazawa, N Muroi… - Journal of The …, 1986 - iopscience.iop.org
New type of electrodes of IrO2/TiOJTi, where the TiO2 films are prepared by the anodic
oxidation accompanied by sparking and are porous, were tested as the anode for the oxygen …

Enhancement of nonlinear optical effect in one-dimensional photonic crystal structures

N Tsurumachi, S Yamashita, N Muroi… - Japanese journal of …, 1999 - iopscience.iop.org
… a factor of (nB/nA)2N /2, where N is the number of periods of A and B bilayers on each side
… enhancement of the order of 102 and 104 for N = 5 and N = 10, respectively. This fact leads …

[HTML][HTML] Risk factors of proteinuria and potentially protective effect of renin–angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib

…, A Matsumoto, M Hirabatake, N Muroi… - Cancer Chemotherapy …, 2022 - Springer
… The exclusion criteria were insufficient data from the urine test (n = 16) or an observational
period less than 1 month after starting axitinib (n = 6). Among the 72 consecutive patients who …